Inhibition of the hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) represents a promising strategy for discovering next-generation treatments for renal anemia. We identified a pyrimidine core with HIF-PHD inhibitory activity based on scaffold hopping of FG-2216 using crystal structures of HIF-PHD2 in complex with compound. By optimizing the substituents at the 2- and 6- positions of the pyrimidine core, we discovered DS44470011, which improves the effectiveness of erythropoietin (EPO) release in cells. Oral administration of DS44470011 to cynomolgus monkeys increased plasma EPO levels.
Keywords: Erythropoietin (EPO); Hypoxia-inducible factor (HIF); Hypoxia-inducible factor prolyl hydroxylase (HIF-PHD); Renal anemia.
Copyright © 2024 Elsevier Ltd. All rights reserved.